Study summary · research use only
Mazdutide: First Approval
Plain-language summary
Paraphrased from the published abstract below — not a verdict on whether anything works.
This article summarizes the regulatory milestones leading to the first approval of mazdutide (Xinermei), a dual glucagon receptor and GLP-1 receptor agonist developed by Eli Lilly and Innovent Biologics. In June 2025, mazdutide was approved in China for long-term body weight management in adults with a BMI of 28 kg/m2 or higher, or 24 kg/m2 or higher with a weight-related comorbidity, alongside diet and physical activity changes. In September 2025, mazdutide was also approved in China for glycaemic control in adults with type 2 diabetes. The article notes mazdutide is under clinical evaluation for metabolic dysfunction-associated fatty liver disease, obstructive sleep apnoea, and alcohol use disorder.
Abstract
Mazdutide (Xinermei®) is a dual glucagon receptor (GcgR) and glucagon-like peptide-1 receptor (GLP-1R) agonist being developed by Eli Lilly and Company along with Innovent Biologics for use in weight management in adults with obesity or overweight and for the treatment of type 2 diabetes (T2D). In June 2025, mazdutide received its first approval, in China, for use (in combination with diet control and increased physical activity) in long-term body weight management in adults with a body-mass index (BMI) of ≥ 28 kg/m2 or with a BMI ≥ 24 kg/m2 together with one or more weight-related comorbidity. Subsequently, in September 2025, mazdutide also received approval in China for use in glycaemic control in adults with T2D. Additionally, mazdutide is under clinical evaluation for use in the treatment of metabolic dysfunction-associated fatty liver disease, obstructive sleep apnoea and alcohol use disorder. This article summarises the milestones in the development of mazdutide leading to this first approval for long-term body weight management in adults with obesity or overweight.
pepmg summarizes the peer-reviewed literature and links to every source — it sells nothing, ships nothing, and gives no medical, dosing, or human-use guidance. Don't just trust this summary: follow the citation to its source and read it yourself. Research use only.